By Finance Pulse in VIRX —

Viracta Therapeutics Downgraded to Neutral by Rodman & Renshaw

Viracta Therapeutics (VIRX) faces a downgrade to Neutral from Buy by Rodman & Renshaw, with a significant price target slash to $0.25 from $3.50, indicating a negative outlook.

A somber financial graph with downward-trending lines, set against a backdrop of stock market ticker
Viracta Therapeutics Downgraded to Neutral by Rodman & Renshaw

Rodman & Renshaw downgraded Viracta Therapeutics to Neutral from Buy, with a price target of 25c, down from $3.50.

Source